**Pharma & Healthcare**

**Description:**

The global Hypolipidemic drugs market is estimated to grow to reach USD 30 billion by 2020. The aging of population and the low-age trend of hyperlipidemia are expected to promote the development of the market during the forecast period.

The market is highly concentrated, few top drugs share the most part of the global market. However, as many big-selling medicines’ patent is expiring or has expired, emerge of the me-too drugs may change the structure of the market, especially in developing countries.

This report studies Hypolipidemic Drugs in Global and China market, focuses on price, sales, revenue of each type in global China. This report also focuses on the sales (consumption), production, import and export of Hypolipidemic Drugs in North America, Japan, Europe, India, Southeast Asia and China, forecast to 2020, from 2015.

Split by product types, with sales, revenue, market share and price of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers, in 2015 and 2016, covering
- Statins
- Fibrates
- Niacin
- Bile Acid Sequetrants
- Polyenes
- Others

Split by manufacturers, this report focuses on the sales, price of each type, average price of Hypolipidemic Drugs, revenue and market share, for each manufacturer in 2015 and 2016. Top players, covering
- Pfizer
- Norvatis
- Merck
- AstraZeneca
- Daiichi-Sankyo
- Sanzoz Inc
- Schwitz Biotech
- Sanofi
- KOS PHARMACEUTICALS
- Genzyme
- Bristol-Myers Squibb
- Jialin Pharmaceutical (China)
- Lunan Pharmaceutical (China)
- Qilu Pharmaceutical (China)
TOPFOUND (China)
Zhejiang Jingxin Pharmaceutical (China)
SIMCERE (China)
Guangzhou Nanxin Pharmaceutical (China)
CINMED Pharmaceuticals (China)
Hisun Pharmaceuticals (China)

Split by regions, this report focuses on the sales (consumption), production, import and export of Hypolipidemic Drugs in North America, Japan, Europe, India and China, from 2011 to 2020 (forecast), covering
North America
Europe
Japan
China
India
Southeast Asia

Split by applications, this report focuses on consumption and growth rate of @@@@ in major applications.
Split by applications, covering
Familial Hyperlipoproteinemia
Acquired Hyperlipoproteinemia

With 136 pages, 168 charts and eight chapters, to display the market present situation and future, clearly and deeply.

Table Of Contents:

Table of Contents

Global and China Hypolipidemic Drugs Research Report to 2020
1 Hypolipidemic Drugs Overview
1.1 Product Overview of Hypolipidemic Drugs
1.1.1 Definition and Product Scope of Hypolipidemic Drugs
1.1.2 Global Market Size (Value and Volume) of Hypolipidemic Drugs 2015-2020
1.1.3 China Market Size (Value and Volume) of Hypolipidemic Drugs 2015-2020
1.2 Classification of Hypolipidemic Drugs
1.2.1 Statins
1.2.2 Fibrates
1.2.3 Niacin
1.2.4 Bile Acid Sequetrants
1.2.5 Polyenes
1.2.6 Others
1.2.7 Market Share and Growth Rate of Each Type
1.3 Key Manufactures and price of Each Type in 2015 and 2016
1.3.1 Key Manufactures of each Type
1.3.2 Price List (Interviewed) of Main Types by Key Manufacturers
1.3.2.1 Statins
1.3.2.2 Fibrates
1.3.2.3 Niacin
1.3.2.4 Bile Acid Sequetrants

2 Competition Analysis by Manufacturers in Global and China
2.1 Global Market Hypolipidemic Drugs Sales and Share List of Key Manufacturers 2015 to 2016
2.2 Global Market Hypolipidemic Drugs Revenue and Share List of Key Manufacturers 2015 to 2016
2.3 Global Hypolipidemic Drugs Average Price List of Key Manufacturers 2015 to 2016
2.4 China Market Hypolipidemic Drugs Sales and Share List of Key Manufacturers 2015 to 2016
2.5 China Market Hypolipidemic Drugs Revenue and Share List of Key Manufacturers 2015 to 2016
2.6 China Hypolipidemic Drugs Average Price List of Key Manufacturers 2015 to 2016

3 Sales and Revenue Segments of Each Type 2015 to 2016
3.1 Global Sales and Revenue Segments of Each Type 2015 to 2016
3.1.1 Global Sales and Market Share of Each Type 2015 to 2016
3.1.2 Global Revenue and Market Share of Each Type 2015 to 2016
3.2 Fibrates Sales and Growth Rate 2015 to 2020
3.3 Niacin Sales and Growth Rate 2015 to 2020
3.4 Bile Acid Sequetrants Sales and Growth Rate 2015 to 2020
3.5 Other Types Sales and Growth Rate 2015 to 2020

4 Market Segments and Forecast of Hypolipidemic Drugs by Regions
4.1 Sales (Consumption) and Forecast of Hypolipidemic Drugs by Regions 2015-2020
4.1.1 Sales and Forecast of Hypolipidemic Drugs by Regions 2015-2020
4.1.2 Sales Growth Rate Forecast of Hypolipidemic Drugs by Regions 2015 to 2020
4.2 Production and Forecast of Hypolipidemic Drugs by Regions 2015 to 2020
4.2.1 Production and Forecast of Hypolipidemic Drugs by Regions 2015 to 2020
4.2.2 Production Growth Rate Forecast of Hypolipidemic Drugs by Regions 2015 to 2020
4.3 North America Market Forecast to 2020
4.3.1 North America Sales (Consumption), Production, Import and Export of Hypolipidemic Drugs 2015 to 2020
4.4 Europe Market Forecast to 2020
4.4.1 Europe Sales (Consumption), Production, Import and Export of Hypolipidemic Drugs 2015 to 2020
4.5 Japan Market Forecast to 2020
4.5.1 Japan Sales (Consumption), Production, Import and Export of Hypolipidemic Drugs 2015 to 2020
4.6 India Market Forecast to 2020
4.6.1 India Sales (Consumption), Production, Import and Export of Hypolipidemic Drugs 2015 to 2020
4.8 China Market Forecast to 2020
4.8.1 China Sales (Consumption), Production, Import and Export of Hypolipidemic Drugs 2015 to 2020

5 Applications
5.1 Applications in Different kinds of Hyperlipoproteinemia
5.1.1 Familial Hyperlipoproteinemia
5.1.2 Acquired Hyperlipoproteinemia
5.1 Applications and Price Scope Interviewed in Major Applications
5.2 Applications and Price Scope Interviewed in Different kinds of Hypertension and Population
5.2.1 Price Scope (Interviewed Price to Buyers) of Hypolipidemic Drugs 2015 and 2016
5.2.2 Consumption and Forecast of Hypolipidemic Drugs 2015 to 2020
5.2.2 Consumption Growth Rate Forecast of Hypolipidemic Drugs in Different kinds of Hypertension and Population 2015 to 2020
5.3.3 Consumption Market Share of Hypolipidemic Drugs in Different kinds of Hypertension and Population 2015 to 2020
5.3 Familial Hyperlipoproteinemia
5.3.1 Familial Hyperlipoproteinemia Analysis
5.3.2 Key Consumers (Buyers) and Contact of Hypolipidemic Drugs in Primary Hypertension
5.4 Familial Hyperlipoproteinemia
5.4.1 Familial Hyperlipoproteinemia Analysis
5.4.2 Key Consumers (Buyers) and Contact of Hypolipidemic Drugs in Secondary Hypertension

6 Key Manufacturers Analysis of Hypolipidemic Drugs
6.1 Pfizer
6.1.1 Company Basic Information
6.1.2 Hypolipidemic Drugs Product Segment of Pfizer
6.1.2.1 Lipitor and Price in 2015 and 2016
6.1.2.2 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM and Price in 2015 and 2016
6.1.2.3 Olbetam and Price in 2015 and 2016
6.1.3 Hypolipidemic Drugs Sales, Revenue, Price of Pfizer 2015 to 2016
6.1.4 Interviewee, Name and Contact
6.2 Norvatis
6.2.1 Company Basic Information
6.2.2 Hypolipidemic Drugs Product Segment of Norvatis
6.2.2.1 Lescol and Price in 2015 and 2016
6.2.3 Hypolipidemic Drugs Sales, Revenue, Price of Norvatis 2015 to 2016
6.2.4 Interviewee, Name and Contact
6.3 Merck
6.3.1 Company Basic Information
6.3.2 Hypolipidemic Drugs Product Segment of Merck
6.3.2.1 ZOCOR and Price in 2015 and 2016
6.3.2.2 Liptruzet and Price in 2015 and 2016
6.3.2.3 MEVACOR and Price in 2015 and 2016
6.3.2.4 VYTORIN and Price in 2015 and 2016
6.3.2.5 ZETIA and Price in 2015 and 2016
6.3.3 Hypolipidemic Drugs Sales, Revenue, Price of Merck 2015 to 2016
6.3.4 Interviewee, Name and Contact
6.4 AstraZeneca
6.4.1 Company Basic Information
6.4.2 Hypolipidemic Drugs Product Segment of AstraZeneca
6.4.2.1 Crestor and Price in 2015 and 2016
6.4.2.2 Plendil, Modip, Splendil, Munobal, Flodil and Price in 2015 and 2016
6.4.3 Hypolipidemic Drugs Sales, Revenue, Price of AstraZeneca 2015 to 2016
6.4.4 Interviewee, Name and Contact
6.5 Daiichi-Sankyo
6.5.1 Company Basic Information
6.5.2 Hypolipidemic Drugs Product Segment of Daiichi-Sankyo
6.5.2.1 WELCHOL and Price in 2015 and 2016
6.5.2.2 Pravastatin and Price in 2015 and 2016
6.5.3 Hypolipidemic Drugs Sales, Revenue, Price of Daiichi-Sankyo 2015 to 2016
6.5.4 Interviewee, Name and Contact
6.6 Sanzoz Inc
6.6.1 Company Basic Information
6.6.2 Hypolipidemic Drugs Product Segment of Sanzoz Inc by Type
6.6.2.1 Atorvastatin and Price in 2015 and 2016
6.6.2.2 Cholestyramine and Price in 2015 and 2016
6.6.2.3 Cholestyramine Light and Price in 2015 and 2016
6.6.3 Hypolipidemic Drugs Sales, Revenue, Price of Sanzoz Inc 2015 to 2016
6.6.4 Interviewee, Name and Contact
6.7 Schwitz Biotech
6.7.1 Company Basic Information
6.7.2 Hypolipidemic Drugs Product Segment of Schwitz Biotech by Type
6.7.2.1 SHIRO-10 and Price in 2015 and 2016
6.7.2.2 SHIEO-CL and Price in 2015 and 2016
6.7.3 Hypolipidemic Drugs Sales, Revenue, Price of Schwitz Biotech 2015 to 2016
6.7.4 Interviewee, Name and Contact
6.8 Sanofi
6.8.1 Company Basic Information
6.8.2 Hypolipidemic Drugs Product Segment of Sanofi

6.8.2.1 Praluent and Price in 2015 and 2016
6.8.3 Hypolipidemic Drugs Sales, Revenue, Price of Sanofi 2015 to 2016
6.8.4 Interviewee, Name and Contact

6.9 KOS PHARMACEUTICALS

6.9.1 Company Basic Information
6.9.2 Hypolipidemic Drugs Product Segment of KOS PHARMACEUTICALS by Type
6.9.2.1 Advicor and Price in 2015 and 2016
6.9.3 Hypolipidemic Drugs Sales, Revenue, Price of KOS PHARMACEUTICALS 2015 to 2016
6.9.4 Interviewee, Name and Contact

6.10 Genzyme

6.10.1 Company Basic Information
6.10.2 Hypolipidemic Drugs Product Segment of Genzyme by Type
6.10.2.1 Kynamro and Price in 2015 and 2016
6.10.3 Hypolipidemic Drugs Sales, Revenue, Price of Genzyme 2015 to 2016
6.10.4 Interviewee, Name and Contact

6.11 Bristol-Myers Squibb

6.11.1 Company Basic Information
6.11.2 Hypolipidemic Drugs Product Segment of Bristol-Myers Squibb by Type
6.11.3 Hypolipidemic Drugs Sales, Revenue, Price of Bristol-Myers Squibb 2015 to 2016
6.11.4 Interviewee, Name and Contact

6.12 Jialin Pharmaceutical (China)

6.12.1 Company Basic Information
6.12.2 Hypolipidemic Drugs Product Segment of Jialin Pharmaceutical
6.12.3 Hypolipidemic Drugs Sales, Revenue, Price of Jialin Pharmaceutical 2015 to 2016

6.13 Lunan Pharmaceutical (China)

6.13.1 Company Basic Information
6.13.2 Hypolipidemic Drugs Product Segment of Lunan Pharmaceutical
6.13.2.2 Zhengzhiping and Price in 2015 and 2016
6.13.3 Hypolipidemic Drugs Sales, Revenue, Price of Lunan Pharmaceutical 2015 to 2016

6.14 Qilu Pharmaceutical (China)

6.14.1 Company Basic Information
6.14.2 Hypolipidemic Drugs Product Segment of Qilu Pharmaceutical
6.14.2.2 Aileting and Price in 2015 and 2016
6.14.3 Hypolipidemic Drugs Sales, Revenue, Price of Qilu Pharmaceutical 2015 to 2016

6.15 TOPFOUND (China)

6.15.1 Company Basic Information
6.15.2 Hypolipidemic Drugs Product Segment of TOPFOUND
6.15.3 Hypolipidemic Drugs Sales, Revenue, Price of TOPFOUND 2015 to 2016

6.16 Zhejiang Jingxin Pharmaceutical (China)
6.16.1 Company Basic Information
6.16.2 Hypolipidemic Drugs Product Segment of Zhejiang Jingxin Pharmaceutical
6.16.3 Hypolipidemic Drugs Sales, Revenue, Price of Zhejiang Jingxin Pharmaceutical 2015 to 2016
6.17 SIMCERE (China)
6.17.1 Company Basic Information
6.17.2 Hypolipidemic Drugs Product Segment of SIMCERE
6.17.3 Hypolipidemic Drugs Sales, Revenue, Price of SIMCERE 2015 to 2016
6.18 Guangzhou Nanxin Pharmaceutical (China)
6.18.1 Company Basic Information
6.18.2 Hypolipidemic Drugs Product Segment of Guangzhou Nanxin Pharmaceutical
6.18.3 Hypolipidemic Drugs Sales, Revenue, Price of Guangzhou Nanxin Pharmaceutical 2015 to 2016
6.19 CINMED Pharmaceuticals (China)
6.19.1 Company Basic Information
6.19.2 Hypolipidemic Drugs Product Segment of CINMED Pharmaceuticals
6.19.3 Hypolipidemic Drugs Sales, Revenue, Price of CINMED Pharmaceuticals 2015 to 2016
6.20 Hisun Pharmaceuticals (China)
6.20.1 Company Basic Information
6.20.2 Hypolipidemic Drugs Product Segment of Hisun Pharmaceuticals
6.20.3 Hypolipidemic Drugs Sales, Revenue, Price of Hisun Pharmaceuticals 2015 to 2016

7 Technology Development Trend
7.1 Manufacturing Process of Hypolipidemic Drugs
7.2 Analysis of Manufacturing Process
7.3 Development Trend

8 Research Findings and Conclusion

List of Tables and Figures

Figure Picture of Hypolipidemic Drugs
Figure Global Market Size (Value) of Hypolipidemic Drugs 2015-2020
Figure Global Market Size (Volume) of Hypolipidemic Drugs 2015-2020
Figure China Market Size (Value) of Hypolipidemic Drugs 2015-2020
Figure China Market Size (Volume) of Hypolipidemic Drugs 2015-2020
Table Market Share of Each Type
Figure Growth Rate of Each Type 2015 to 2016
Table Price List (Interviewed) of Type 1 by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of ARB by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of ARB by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of ACE-I by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of ACE-I by Key Manufacturers in 2015 and 2016
Table Global Market Hypolipidemic Drugs Sales List of Key Manufacturers 2015 to 2016
Table Global Market Hypolipidemic Drugs Sales Share List of Key Manufacturers 2015 to 2016
Table Global Market Hypolipidemic Drugs Revenue List of Key Manufacturers 2015 to 2016
Table Global Market Hypolipidemic Drugs Revenue Share List of Key Manufacturers 2015 to 2016
Table Global Hypolipidemic Drugs Average Price List of Key Manufacturers 2015 to 2016
Table China Market Hypolipidemic Drugs Sales List of Key Manufacturers 2015 to 2016
Table China Market Hypolipidemic Drugs Sales Share List of Key Manufacturers 2015 to 2016
Table China Market Hypolipidemic Drugs Revenue List of Key Manufacturers 2015 to 2016
Table China Market Hypolipidemic Drugs Revenue Share List of Key Manufacturers 2015 to 2016
Table China Hypolipidemic Drugs Average Price List of Key Manufacturers 2015 to 2016
Table Global Sales of Each Type 2015 to 2016
Table Global Sales Market Share of Each Type 2015 to 2016
Table Global Revenue of Each Type 2015 to 2016
Table Global Revenue Market Share of Each Type 2015 to 2016
Figure CCB Sales and Growth Rate 2015 to 2020
Figure ACE-I Sales and Growth Rate 2015 to 2020
Figure ARB Sales and Growth Rate 2015 to 2020
Figure Adrenergic Receptor Antagonists Sales and Growth Rate 2015 to 2020
Figure ARB Sales and Growth Rate 2015 to 2020
Table Sales and Forecast of Hypolipidemic Drugs by Regions 2015-2020
Table Sales and Forecast of Hypolipidemic Drugs by Regions 2015-2020
Figure Sales Growth Rate Forecast of Hypolipidemic Drugs by Regions 2015 to 2020
Table Production and Forecast of Hypolipidemic Drugs by Regions 2015 to 2020
Table Production and Forecast of Hypolipidemic Drugs by Regions 2015 to 2020
Figure Production Growth Rate Forecast of Hypolipidemic Drugs by Regions 2015 to 2020
Table North America Sales, Production, Import and Export of Hypolipidemic Drugs 2015 to 2020
Table Europe Sales, Production, Import and Export of Hypolipidemic Drugs 2015 to 2020
Table Japan Sales, Production, Import and Export of Hypolipidemic Drugs 2015 to 2020
Table India Sales, Production, Import and Export of Hypolipidemic Drugs 2015 to 2020
Table China Sales, Production, Import and Export of Hypolipidemic Drugs 2015 to 2020
Table Price Scope (Interviewed Price to Buyers) of Hypolipidemic Drugs in Major Applications 2015 and 2016
Table Consumption and Forecast of Hypolipidemic Drugs in Major Applications 2015 to 2020
Table Consumption and Forecast of Hypolipidemic Drugs in Major Applications 2015 to 2020
Figure Consumption Growth Rate Forecast of Hypolipidemic Drugs in Major Applications 2015 to 2020
Table Consumption Market Share of Hypolipidemic Drugs in Major Applications 2015 to 2020
Table Key Consumers (Buyers) and Contact of Hypolipidemic Drugs in Application 1
Table Key Consumers (Buyers) and Contact of Hypolipidemic Drugs in Secondary Hypertension
Table Pfizer Basic Information List
Table Hypolipidemic Drugs Sales, Revenue, Price of Pfizer 2015 to 2016
Table Norvatis Basic Information List
Table Hypolipidemic Drugs Sales, Revenue, Price of Norvatis 2015 to 2016
Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.